Overview

A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
Phase:
Phase 2
Details
Lead Sponsor:
Watson Pharmaceuticals
Treatments:
Silodosin